Mangione moves to dismiss N.Y. state murder case – One America News Network


NEW YORK, NEW YORK - AUGUST 11: Luigi Mangione attends a pre-trial appearance at Manhattan Criminal Court on August 11, 2026 in New York City. Mangione is accused of fatally shooting UnitedHealthcare CEO Brian Thompson and faces state and federal murder charges. (Photo by David Dee Delgado-Pool/Getty Images)
Luigi Mangione attends a pre-trial appearance at Manhattan Criminal Court on August 11, 2026 in New York City. Mangione is accused of fatally shooting UnitedHealthcare CEO Brian Thompson and faces state and federal murder charges. (Photo by David Dee Delgado-Pool/Getty Images)

OAN Staff Sophia Flores 
10:45 AM – Friday, August 14, 2026

Luigi Mangione’s defense team has filed a motion to dismiss his New York state charges following his guilty plea in federal court over the death of UnitedHealthcare CEO Brian Thompson.

On Friday, following a surprise federal court hearing where Mangione pleaded guilty — just weeks before his federal trial was set to begin — his lawyers revealed that they moved to have the state case dismissed.

By admitting guilt and resolving the federal case, his defense team was able to invoke New York’s double jeopardy protections.

Under state law, double jeopardy can be triggered once a defendant enters a guilty plea in a federal prosecution arising from the same underlying conduct.

 

In the federal case, Mangione pleaded guilty to stalking resulting in death, which carries a maximum punishment of life in prison. In his state case, which the defense is asking to drop, Mangione faces second-degree murder charges carrying a sentence of 25 years to life.

His New York trial is currently scheduled to begin on September 8, 2026.

Stay informed! Receive breaking news alerts directly to your inbox for free. Subscribe here. https://www.oann.com/alerts

 

What do YOU think? Click here to jump to the comments!

 


Sponsored Content Below

 

Share this post!





Source link

Sophia Flores
Author: Sophia Flores

Be the first to comment

Leave a Reply

Your email address will not be published.


*